Imatinib Related Severe Anaemia In a Case of Chronic Myeloid Leukaemia in Complete Molecular Response
Abstract
Chronic myeloid leukaemia is a clonal
haematopoietic disorder caused by reciprocal
translocation of chromosomes 9
and 22 . Imatinib , a small molecule tyrosine
kinase inhibitor, targeting BCR-ABL
tyrosine kinase is the first line treatment
of CML. Myelosuppression is a common
adverse effect of imatinib usually seen in
the initial 2-4 weeks of treatment. However,
severe anemia in a patient in cytogenetic
and molecular response is rare .
Here we present a case who developed
persistent and severe anemia with
imatinib after 5 years of treatment and
after attaining complete molecular responseEvaluation
of anaemia failed to
reveal any other cause and withdrawal of
imatinib led to improvement in anemia,
hence implicating the drug in the causation
of anaemia. The case highlights the
need for constant monitoring of adverse
effects even in commonly prescribed
drugs after several years of treatment .
Full Text:
PDFReferences
Brian J. Druker and Stephanie J. Lee:
Chronic myelogenous leukaemia: Devita,
Hellman and Rosenber sCancer, Principles
and practice of oncology, 9th edition:
Sawyers CL. Chronic myeloid leukemia:.
N Engl J Med 1999;340:1330–40
Druker BJ. Translation of the Philadelphia
chromosome into therapy for
CML.Blood 2008;112:4808
irota S , Isozaki K, Moriyama Y, et
al. Gain-of-function mutations of c-kit
in human gastrointestinal stromal tumours.
Science 1998; 279(5350):577
Demetri GD, von Mehren M, Blanke
CD,et al. Efficacy and safety of
imatinib mesylate in advanced gastrointestinal
stromal tumors.: N Engl J
Med 2002;347:472–80
Kantarjian HM, Sawyers C,
Hohchhaus A,et al. Hematologic and
cytogenetic responses to imatinib
mesylate in chronic myelogenous
leukemia.: N Engl J Med
;346:645–52.
Guilhot F. Indications for imatinib
mesylate therapy and clinical management.
Oncologist 2004;9:271–81.
Cortes J , O'Brien S, Quintas A,
Giles F, Shan J, Rios MB, Talpaz M,
Kantarjian H .Erythropoietin is effective
in improving the anemia induced
by imatinib mesylate therapy in patients
with chronic myeloid leukemia
in chronic phase. Cancer.2004 Jun
;100(11):2396-402
Michael W. N. Deininger.: ASH
education book.: 2005/1/174
Shafik Khouri MD1, Andy Kotliroff
MD2, Michael Lishner MD2 and Howard
Amital MD MHA1 .Imatinib-
Induced Agranulocytosis in a Patient
with Chronic Myelogenous Leukemia
in Remission .IMAJ 2008;10:320–321
Bartolovic K, Balabanov S, Hartmann
U,et al. Inhibitory effect of imatinib on
nomal progenitor cells in vitro. :Blood
;103:523
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University